970 Medicine. 2016;12(17):958-70
ENFERMEDADES ENDOCRINOLÓGICAS Y METABÓLICAS
(
V
)
32. Genuth S. Insights from the diabetes control and complications trial/
epidemiology of diabetes interventions and complications study on the
use of intensive glycemic treatment to reduce the risk of complications of
type 1 diabetes. Endocr Pract. 2006;12Suppl1:34-41.
33.
t
Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-
Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. N
Engl J Med. 2005;352(4):341-50.
✔
34. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy:
Mechanisms to management. Pharmacol Ther. 2008;120(1):1-34.
✔
35. Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end
products in diabetic neuropathy. Curr Pharm Des. 2008;14(10):953-61.
✔
36. Oates PJ. Aldose reductase, still a compelling target for diabetic neuro-
pathy. Curr Drug Targets. 2008;9(1):14-36.
✔
37. Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the
pathogenesis of diabetic neuropathy. Endocr Rev. 2004;25(4):612-28.
✔
38. Kennedy JM, Zochodne DW. Impaired peripheral nerve regeneration in
diabetes mellitus. J Peripher Nerv Syst. 2005;10(2):144-57.
39. Early photocoagulation for diabetic retinopathy. ETDRS report number
9. early treatment diabetic retinopathy study research group. Ophthalmo-
logy. 1991;98(5)Suppl:766-85.
✔
40. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlin-
gemann RO et al. The RESTORE study: Ranibizumab monotherapy or
combined with laser versus laser monotherapy for diabetic macular ede-
ma. Ophthalmology. 2011;118(4):615-25.
✔
41. Nentwich MM, Yactayo-Miranda Y, Schwarzbach F, Wolf A, Kampik A,
Mino de Kaspar H. Endophthalmitis after intravitreal injection: Decrea-
sing incidence and clinical outcome-8-year results from a tertiary
ophthalmic referral center. Retina. 2014;34(5):943-50.
✔
42. Boyer DS, Yoon YH, Belfort R,Jr, Bandello F, Maturi RK, Augustin AJ, et
al. Three-year, randomized, sham-controlled trial of dexamethasone in-
travitreal implant in patients with diabetic macular edema. Ophthalmolo-
gy. 2014;121(10):1904-14.
43. Photocoagulation treatment of proliferative diabetic retinopathy. clinical
application of diabetic retinopathy study (DRS) findings, DRS report
number 8. the diabetic retinopathy study research group. Ophthalmology.
1981;88(7):583-600.
✔
44. Simo R, Hernández C, European Consortium for the Early Treatment of
Diabetic Retinopathy (EUROCONDOR). Neurodegeneration in the
diabetic eye: New insights and therapeutic perspectives. Trends Endocri-
nol Metab. 2014;25(1):23-33.
✔
45. Sfikakis PP, Grigoropoulos V, Emfietzoglou I, Theodossiadis G, Tento-
louris N, Delicha E, et al. Infliximab for diabetic macular edema refrac-
tory to laser photocoagulation: A randomized, double-blind, placebo-
controlled, crossover, 32-week study. Diabetes Care. 2010;33(7):1523-8.
✔
46. Liu J, Feener EP. Plasma kallikrein-kinin system and diabetic retinopathy.
Biol Chem. 2013;394(3):319-28.
✔
47.
tt
Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen
O. Multifactorial intervention and cardiovascular disease in patients
with type 2 diabetes. N Engl J Med. 2003;348(5):383-93.
✔
48. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-
Fuchs J,et al. Diabetic kidney disease: A report from an ADA consensus
conference. Am J Kidney Dis. 2014;64(4):510-33.
✔
49. Writing Team for the Diabetes Control and Complications Trial/Epide-
miology of Diabetes Interventions and Complications Research Group.
Effect of intensive therapy on the microvascular complications of type 1
diabetes mellitus. JAMA. 2002;287(19):2563-9.
50. Skupien J, Warram JH, Smiles A, Galecki A, Stanton RC, Krolewski AS.
Improved glycemic control and risk of ESRD in patients with type 1
diabetes and proteinuria. J Am Soc Nephrol. 2014;25(12):2916-25.
✔
51. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of
mild-to-moderate renal insufficiency. Diabetes Care. 2011;34(6):1431-7.
✔
52. Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q,et al.
Intensive glucose control improves kidney outcomes in patients with type
2 diabetes. Kidney Int. 2013;83(3):517-23.
53.
tt
Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel
A. Blood pressure lowering in type 2 diabetes: A systematic review
and meta-analysis. JAMA. 2015;313(6):603-15.
✔
54.
t
Tight blood pressure control and risk of macrovascular and mi-
crovascular complications in type 2 diabetes: UKPDS 38. UK pros-
pective diabetes study group. BMJ. 1998;317(7160):703-13.
✔
55. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al.
Telmisartan to prevent recurrent stroke and cardiovascular events. N
Engl J Med. 2008;359(12):1225-37.
✔
56. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, So-
lomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2
diabetes. N Engl J Med. 2012;367(23):2204-13.
✔
57. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA,
Livingstone SJ, et al. Effects of atorvastatin on kidney outcomes and car-
diovascular disease in patients with diabetes: An analysis from the colla-
borative atorvastatin diabetes study (CARDS). Am J Kidney Dis.
2009;54(5):810-9.
✔
58.
t
Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan
DR, et al. Effects of fenofibrate on renal function in patients with
type 2 diabetes mellitus: The fenofibrate intervention and event
lowering in diabetes (FIELD) study. Diabetología. 2011;54(2):280-
90.
✔
59. Mychaleckyj JC, Craven T, Nayak U, Buse J, Crouse JR, Elam M, et al.
Reversibility of fenofibrate therapy-induced renal function impairment in
ACCORD type 2 diabetic participants. Diabetes Care. 2012;35(5):1008-
14.
✔
60. Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist
nephrology services for preventing the progression to end-stage kidney
disease. Cochrane Database Syst Rev. 2014;6:CD007333.
✔
61.
t
Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the phar-
macological treatment of neuropathic pain: 2010 revision. Eur J
Neurol. 2010;17(9):1113-e88.
✔
62.
t
Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro
D, et al. Evidence-based guideline: Treatment of painful diabetic
neuropathy: Report of the american academy of neurology, the ame-
rican association of neuromuscular and electrodiagnostic medicine,
and the american academy of physical medicine and rehabilitation.
Neurology. 2011;76(20):1758-65.
✔
63. Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG,
et al. 2012 infectious diseases society of america clinical practice guideline
for the diagnosis and treatment of diabetic foot infections. Clin Infect
Dis. 2012;54(12):e132-73.
64. FDA requires boxed warning and risk mitigation strategy for metoclopra-
mide-containing drugs agency warns against chronic use of these pro-
ducts to treat gastrointestinal disorders. Disponible en: http://www.fda.
gov/newsevents/newsroom/pressannouncements/ucm149533.htm. Up-
dated 20092016.
65. Ekinci EI, Jerums G, Skene A, Crammer P, Power D, Cheong KY, et al.
Renal structure in normoalbuminuric and albuminuric patients with type 2
diabetes and impaired renal function. Diabetes Care. 2013;36(11):3620-6.